Going on trial

Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

New template streamlines sharing clinical trial results

This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.

By Calli McMurray
31 October 2023 | 7 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Looking at eye tracking’s potential for clinical trials

This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.

By Calli McMurray
28 September 2023 | 6 min read
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Trials test utility of EEG biomarkers for autism-related conditions

This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.

By Calli McMurray
31 August 2023 | 7 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

How organ-on-a-chip models can help drug development

This month’s Going on Trial newsletter explores how organ-on-a-chip models could smooth the transition from preclinical to clinical trials, among other drug development news.

By Calli McMurray
31 July 2023 | 5 min read
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Going on Trial: Gene therapy for Rett; return to arbaclofen

This month’s newsletter looks at the early safety data from the first gene therapy trial for Rett syndrome, among other drug development news.

By Calli McMurray
29 June 2023 | 6 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Going on Trial: Epidiolex for autism; arbaclofen tests; pain monitoring

This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.

By Peter Hess
30 May 2023 | 7 min read
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data

This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.

By Peter Hess
28 April 2023 | 7 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.
Spectrum Microphone

Going on Trial: Trofinetide approval for Rett; n-of-1 ASO therapies; cord-blood deals

This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.

By Peter Hess
30 March 2023 | 8 min read
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Going on Trial: Orphan drugs; CBD; bumetanide

This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.

By Peter Hess
28 February 2023 | 7 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

By Peter Hess
25 January 2023 | 6 min read

Explore more from The Transmitter

Brain organoid size matches intensity of social problems in autistic people

Overgrown organoids could point to mechanisms underlying profound autism.

By Holly Barker
18 July 2024 | 5 min read

Persistent protein pairing enables memories to last

The complex of two memory proteins, rather than the individual molecules acting independently, underlie month-long memories in mice, a new study suggests.

By Elissa Welle
17 July 2024 | 5 min read
A digitally distorted image of a file folder against a blue gradient background.

Data access changes to UK Biobank stir unease in neuroscientists

“I feel a little bit in limbo,” says neuroscientist Stephanie Noble, who has paused a study using Biobank data after the repository shifted from a data download to a cloud-only access model.

By Calli McMurray
16 July 2024 | 7 min read